Navigation Links
Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
Date:12/7/2007

HAYWARD, Calif., Dec. 7 /PRNewswire/ -- Acologix, Inc., a privately held biopharmaceutical company, today announced preclinical study results demonstrating that AC-100, its novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells, promoted cartilage regeneration in an animal model. The data was presented by Dr. Catherine Middleton-Hardie at the Osteoarthritis Research Society International (OARSI) 2007 World Congress on Osteoarthritis in Fort Lauderdale, Florida during the poster sessions.

In this study, goats with an osteochondral femoral condylar (knee cartilage) defect were used to evaluate the effects of AC-100 on cartilage regeneration. Cylindrical defects were created in the knee cartilage and were filled with a collagen sponge containing AC-100 at two different doses or a collagen sponge soaked in saline (control group). Post-operative treatments included intra-articular injections of the test articles into the operated knee joint at weeks one, two and three post surgery. Cartilage regeneration was evaluated in one group after 84 days and 168 days in another group.

The results demonstrated that the application of AC-100 dose dependently promoted cartilage defect repair. The groups treated with the higher dosage of AC-100 had greater healing outcome scores than the saline control groups. As there was no evidence of an inflammatory response, AC-100 demonstrated a favorable safety profile in the study.

These results follow a reported Phase II clinical trial that demonstrated AC-100 stimulates the formation of new dentin (the hard tissue of teeth that protects the tooth pulp and supports the outer enamel) when applied directly to tooth defects (prepared cavities).

"We are very pleased to see this type of response to AC-100 in such a challenging model. This is the first demonstration of AC-100 to promote cartilage repair. These findings are consistent with previous studies where AC-100 ha
'/>"/>

SOURCE Acologix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... 2013 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... President and Chief Executive Officer of Neurocrine Biosciences, will be ... Health Care Conference in Boston.   The live ... Eastern Time / 8:20 a.m. Pacific Time.  The presentation will ... at http://www.neurocrine.com . If you are ...
(Date:5/23/2013)... THOUSAND OAKS, Calif. , May 23, 2013 ... Deutsche Bank 38 th Annual  Healthcare Conference on Thursday, ... Boston , beginning at 9:20 a.m. Eastern Daylight ... Investor Relations at Amgen, will present at the conference. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. A ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Mass. and TOKYO, Nov. 10 Ironwood Pharmaceuticals, ... they have entered into an agreement providing Astellas ... compound linaclotide in Japan, Indonesia, Korea, the Philippines, ... 3 clinical development in the United States for ...
... Inc. today announced that it has enrolled the 100th patient ... stenosis. "We are well ahead of our projections for 2009," ... the market need, the clinical outcomes that surgeons are seeing, ... Over 1.5 million people are diagnosed with lumbar spinal stenosis ...
Cached Medicine Technology:Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide 2Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide 3Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study 2
(Date:5/23/2013)... Mayo Clinic researchers have used next generation genomic analysis ... cancer tumors have similar genetic origins, which may help ... in the journal Cancer Research . , "This ... next generation sequencing in adjacent Gleason patterns in the ... in pathology," says ,John Cheville, M.D., Mayo Clinic pathologist ...
(Date:5/23/2013)... Transvaginal mesh lawsuit claims ... move forward in a federal multidistrict litigation underway in ... Liebhard LLP reports. In an Order issued on ... Bard to seal emails that included supplier information the ... proprietary information about its suppliers. The emails were filed ...
(Date:5/23/2013)... 2013 The vast majority of Americans ... control over their level of physical activity, the healthfulness ... are actually taking that control. Those are among ... Foundation’s 2013 Food & Health Survey. , According to ... to have “a great deal of control” or “complete ...
(Date:5/23/2013)... On April 29th, 2013, UV Technologies ... of H7N9 cases and deaths. The headline read, " UV ... Subside in Northern Hemisphere as Available Daylight Increases .” In ... reported. , Quoting Kevin McGuire, president of UV Technologies, ... budding in the spring and leaves changing in the fall. ...
(Date:5/23/2013)... Cheap Concert Tickets announces that Paul ... at stadiums throughout North America. This well known ticket ... concert tickets to help McCartney fans see Sir Paul live ... states that she is also offering the customer appreciation code ... a baby boomer, she is also a huge McCartney fan ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2
... Journal of Clinical Dentistry Demonstrate, Significant Cavity-Fighting ... N.Y. and STONY BROOK, N.Y., April 8, 2008 ... announced today that,new data published in the most ... the effects of a new chewable mint in ...
... Three-year demonstration project will test effectiveness of ... of chronic illness in the,Medicare population, ... Board: HFIT) announced today it is working ... of Pfizer Inc., as part of a,three-year ...
... Huckabee Share Behavior Change Successes ... and Discuss Healthcare Strategies and Trends, PALM SPRINGS, ... in scalable behavior change interventions with outcomes,kicked off ENGAGE ... 250 industry experts and leading employers and health plans,throughout ...
... be the greatest advance in waking up since coffee, ... wake up,in the morning feeling refreshed and ready to go, ... performance to spousal,relations and even driving ability. Fortunately, a unique ... a pill you take before,bedtime that will help you to ...
... 2008 Take a look in your,medicine cabinet ... so, are,you contributing to the nation,s dramatic increase ... National Drug Control,Strategies Report, 71 percent of prescription ... friends. Among 12- to 13-year-olds,prescription drug abuse actually ...
... The appearance of a cold sore is,a sign ... more serious,illnesses emerge, according to John Sherman, ND, noted ... Worldwide, between 80% and 90% of the adult population ... according to Dr. Sherman, who,is the author of The ...
Cached Medicine News:Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 2Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 3Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 4Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 2Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 3Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 4Health News:HealthMedia Kicks Off ENGAGE Conference 2Health News:HealthMedia Kicks Off ENGAGE Conference 3Health News:Tired Mother Invents Pill to Wake You Up On Time 2Health News:Prescription Drug Abuse Threatens Availability of Pain Medication 2Health News:A Cold Sore Is Often A Warning Sign of Deeper Health Issues, Expert Says 2